<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589600</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15070573 (ZEST II)</org_study_id>
    <secondary_id>1R01AG050302-01A1</secondary_id>
    <nct_id>NCT02589600</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)</brief_title>
  <acronym>ZEST II</acronym>
  <official_title>ZEST II for Osteoporotic Fracture Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to perform the first fracture reduction clinical trial with a
      potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term
      care population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although close to 85% of frail women in long-term care (LTC) facilities have osteoporosis and
      the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few
      are treated and studies are scarce. It is postulated that in frail, LTC women an annual
      infusion of zoledronic acid, an antiresorptive therapy for osteoporosis, will:

        1. be effective demonstrated by fracture reduction;

        2. be safe.

      To address these hypotheses, up to 1000 female LTC residents age 65 and older will be
      screened in order to enroll 514 eligible for randomization in a 3 year, randomized,
      double-blind, calcium and vitamin D controlled trial with the antiresorptive agent zoledronic
      acid. Use of an intravenous, once yearly agent avoids concerns of oral bisphosphonate side
      effects, poor absorption and burden on staff. Participants will reside in the long-term care
      settings associated with the Division of Geriatric Medicine, University of Pittsburgh and
      will include women with multiple comorbid conditions, functional and cognitive impairment,
      and limited mobility.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total non-traumatic incident fractures (vertebral and nonvertebral) except those viewed as severe trauma, cancer-related or fractures of the toes, finger or facial bones as identified by x-ray, CT, MRI, VFA imaging.</measure>
    <time_frame>3 years</time_frame>
    <description>Primary outcome will be assessed in all randomized women, optimally obtaining partial data in terms of person months of exposure and corresponding counts of fractures for analysis from those expiring/dropping out/moving before 3 years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">514</enrollment>
  <condition>Osteoporotic Fractures</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Active Medication Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Annual intravenous 5.0 mg</description>
    <arm_group_label>Active Medication Group</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>800 IU daily</description>
    <arm_group_label>Active Medication Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium</intervention_name>
    <description>approximately 1200 mg (dietary and supplement)</description>
    <arm_group_label>Active Medication Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Annual intravenous saline placebo</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women age ≥65 years including those using assistive devices to maximize
             generalizability if they:

               1. Reside in long-term care (LTC);

               2. Have:

                    -  osteoporosis by axial bone density (spine, hip or forearm bone mineral
                       density (BMD) T-score ≤ -2.5 SD); or

                    -  a previous adult fragility fracture of the spine or hip; or,

                    -  would be treated based on FRAX National Osteoporosis Foundation (NOF)
                       treatment thresholds of a 10 year risk of ≥ 20% for a major osteoporotic
                       fracture or ≥ 3% for hip fracture using femoral neck BMD.

        Exclusion Criteria:

          -  Men because osteoporosis is less common in men and our initial ZEST 1 study only
             included women.

          -  Institutionalized women with subacute illnesses surviving or discharged in &lt; 3 years.

          -  Women currently on bisphosphonate, denosumab, or teriparatide therapy or who have been
             on a bisphosphonate for greater than 1 year during the previous 2 years because
             bisphosphonates are long acting.

          -  Patients with a calculated creatinine clearance &lt; 35 ml/min or who have a
             contraindication for bisphosphonates (allergy, hypocalcemia).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan L Greenspan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie M Wagner, PA-C, MPA</last_name>
    <phone>412-692-2478</phone>
    <email>wagnerjm@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dory Adams, MFA</last_name>
    <phone>412-692-2480</phone>
    <email>dja21@pitt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Osteoporosis Prevention &amp; Treatment Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Wagner, PA-C, MPA</last_name>
      <phone>412-692-2478</phone>
      <email>wagnerjm@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dory Adams, MFA</last_name>
      <phone>412-692-2480</phone>
      <email>dja21@pitt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan L Greenspan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Susan L. Greenspan</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Bone loss</keyword>
  <keyword>Frail Geriatric Women</keyword>
  <keyword>Nursing Home Patients</keyword>
  <keyword>Long-term Care Patients</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteoporotic Fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

